An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After First (1st)-Line Treatment With Bevacizumab Plus a Platinum Doublet-containing Chemotherapy

Inclusion Criteria:

- Adult patients, age >/=18 years

- Histologically or cytologically confirmed non-squamous non-small cell lung cancer
(NSCLC)

- Documented progression of disease (locally recurrent or metastatic) per investigator
assessment following first-line treatment 4-6 cycles of Avastin plus a platinum
doublet-containing chemotherapy regimen and a minimum of 2 cycles of Avastin
(monotherapy) maintenance treatment prior to first progression of disease

- No treatment interruption of Avastin treatment greater than 2 consecutive cycles (42
days) between the start of first-line treatment to start of Cycle 1 of second line
treatment

- Randomization within 4 weeks of progression of disease

- At least one unidimensionally measurable lesion meeting RECIST criteria

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

Exclusion Criteria:

- Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a
predominant squamous component

- History of hemoptysis >/=grade 2 within 3 months of randomization

- Major cardiac disease